Regenxbio reports Q3 EPS ($1.41), consensus ($1.49)

Reports Q3 revenue $28.9M, consensus $27.19M. As a result of the portfolio prioritization and corporate restructuring, REGENXBIO anticipates total savings of at least $100M over the next two years. These anticipated cost savings along with $365M in cash, cash equivalents and marketable securities as of September 30, 2023 are now expected to fund operations into the second half of 2025. This cash runway guidance is based on the Company’s current operational plans and excludes the impact of any payments that may be received from AbbVie upon the achievement of development or commercial milestones under our ABBV-RGX-314 collaboration.